Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Abstract In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficacy of auto-HCT vs. CAR-T in patients with DLBCL in a...

Full description

Bibliographic Details
Published in:	Blood Cancer Journal
Main Authors:	Mazyar Shadman, Kwang W. Ahn, Manmeet Kaur, Lazaros Lekakis, Amer Beitinjaneh, Madiha Iqbal, Nausheen Ahmed, Brian Hill, Nasheed M. Hossain, Peter Riedell, Ajay K. Gopal, Natalie Grover, Matthew Frigault, Jonathan Brammer, Nilanjan Ghosh, Reid Merryman, Aleksandr Lazaryan, Ron Ram, Mark Hertzberg, Bipin Savani, Farrukh Awan, Farhad Khimani, Sairah Ahmed, Vaishalee P. Kenkre, Matthew Ulrickson, Nirav Shah, Mohamed A. Kharfan-Dabaja, Alex Herrera, Craig Sauter, Mehdi Hamadani
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-07-01
Online Access:	https://doi.org/10.1038/s41408-024-01084-w

Similar Items

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
by: Madiha Iqbal, et al.
Published: (2022-01-01)

A comprehensive review of the role of bone marrow biopsy and PET-CT in the evaluation of bone marrow involvement in adults newly diagnosed with DLBCL
by: Ruah Alyamany, et al.
Published: (2024-03-01)

CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
by: Matthew J Frigault, et al.
Published: (2025-06-01)

Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
by: Nirav N. Shah, et al.
Published: (2018-04-01)

The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time
by: Ruah AlYamany, et al.
Published: (2022-05-01)

Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit
by: Matthew Mei, et al.
Published: (2022-02-01)

DLBCL Coast to Coast
by: Melania Tesio
Published: (2018-02-01)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
by: Nirav Shah, et al.
Published: (2023-08-01)

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
by: Kharfan-Dabaja Mohamed A, et al.
Published: (2013-01-01)

Sequential Immune Thrombocytopenia (ITP) and Thrombotic Thrombocytopenic Purpura (TTP) in an Elderly Male Patient with Primary Sjogren’s Syndrome: When in Doubt, Use the PLASMIC Score
by: Devon D. Miller, et al.
Published: (2021-01-01)

Regulation and therapy: the role of ferroptosis in DLBCL
by: Yifan Wang, et al.
Published: (2025-01-01)

Cardiac Involvement by HIV-Associated DLBCL
by: Charles T. Mupamombe, et al.
Published: (2018-01-01)

CNS prophylaxis is (mostly) futile in DLBCL
by: Kevin Shieh, et al.
Published: (2024-10-01)

The evaluation of ARG expression in DLBCL staging
by: Faribourz Mokarian, et al.
Published: (2008-12-01)

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
by: Julio C. Chavez, et al.
Published: (2022-09-01)

Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas
by: Ibrahim N. Muhsen, et al.
Published: (2022-06-01)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
by: Joanna Zurko, et al.
Published: (2022-07-01)

Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
by: Razan Mohty, et al.
Published: (2024-12-01)

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
by: Mohamed A. Kharfan-Dabaja, et al.
Published: (2019-03-01)

Spontaneous Remission and Concomitant Progression in a Patient with DLBCL
by: Eun Ji Han, et al.
Published: (2020-11-01)

Influence of corticosteroid treatment on CXCR4 expression in DLBCL
by: Sebastian Martin, et al.
Published: (2023-05-01)

Gastric DLBCL clonal evolution as function of patient age
by: Irina Iosselevitch, et al.
Published: (2022-08-01)

Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
by: Caroline A. Coughlin, et al.
Published: (2025-02-01)

Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings
by: Matthew Ulrickson, et al.
Published: (2012-01-01)

Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients
by: Qing Shi, et al.
Published: (2017-01-01)

Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes
by: Najmeh Heshmatpour, et al.
Published: (2024-10-01)

Mechanism of Action of circRNA/miRNA Network in DLBCL
by: Elena Golovina, et al.
Published: (2025-03-01)

TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL
by: PIMJAI NIPARUCK
Published: (2021-10-01)

Computational modeling of DLBCL predicts response to BH3-mimetics
by: Ielyaas Cloete, et al.
Published: (2023-06-01)

Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
by: Kerstin Wenzl, et al.
Published: (2024-06-01)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: M. Hamadani, et al.
Published: (2022-06-01)

Targeting RPLP2 Triggers DLBCL Ferroptosis by Decreasing FXN Expression
by: Jiaxing Guo, et al.
Published: (2025-05-01)

Injectable Magnetic-Nanozyme Based Thermosensitive Hydrogel for Multimodal DLBCL Therapy
by: Min Yan, et al.
Published: (2025-03-01)

EccDNA, STING activation, and their potential roles in DLBCL prognosis and therapy
by: Xi‐Bo Hu, et al.
Published: (2024-10-01)

Targeting fucosyltransferase FUT8 as a prospective therapeutic approach for DLBCL
by: Hao Xu, et al.
Published: (2025-01-01)

P1596: PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL
by: E. M. Packness, et al.
Published: (2022-06-01)

Combining Obinutuzumab With Radiation for Refractory DLBCL: Retrospective Safety and Efficacy Analysis
by: Brett A. Morris, MD, PhD, et al.
Published: (2024-07-01)

Antitumor Effects of Poplar Propolis on DLBCL SU-DHL-2 Cells
by: Xiaoqing Liu, et al.
Published: (2023-01-01)

CNS Involvement of DLBCL Presenting with an Unusual Non-Enhancing Infiltrative Mass
by: Fu-Sheng Hsueh, et al.
Published: (2023-11-01)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
by: Guido Lancman, et al.
Published: (2018-01-01)